Login To Your Account

Template_Rail_Images

Latest News

DoD Tick-Borne Disease Research Funding Opportunities

Thursday, May 25, 2017
As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
» Continue Reading
 

DoD Tuberous Sclerosis Complex Research Program Funding Opportunities

Thursday, May 25, 2017
FY17 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressio
» Continue Reading
 

DoD Gulf War Illness Research Funding Opportunities

Monday, May 22, 2017
FY17 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally
» Continue Reading
Print

DoD Lung Cancer Research Program Announcement

May 16, 2017 03:51 PM
 

Defense Health Program
Department of Defense Lung Cancer Research Program

Funding Opportunities for Fiscal Year 2017 (FY17)

 

FY17 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

Applications submitted to the FY17 LCRP must address at least one of the seven Areas of Emphasis listed below:

  • Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.
  • Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer.  Screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.
  • Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
  • Identify innovative strategies for prevention and treatment of early and/or localized lung cancer.
  • Understand predictive and prognostic markers to identify responders and nonresponders.
  • Understand susceptibility or resistance to treatment.
  • Understand contributors to lung cancer development other than tobacco.

 

Military Relevance:  The FY17 LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families.  Military relevance will be considered in determining relevance to the mission of the DHP and FY17 LCRP during programmatic review.  Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

  • Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research.
  • Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators.
  • Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area.
  • Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population.
  • Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco.

 

Concept Award – Letter of Intent due July 27

Investigators at all academic levels

Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer

Emphasis on innovation

Clinical trials not allowed

Preliminary data discouraged

Military relevance strongly encouraged

Maximum funding of $100,000 in direct costs (plus indirect costs)

Period of performance should not exceed 1 year

 

Career Development Award – Letter of Intent due September 13

Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment

Mentor:  At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research

Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher

Clinical trials not allowed

Preliminary data not required

Military relevance strongly encouraged

Maximum funding of $250,000 in direct costs (plus indirect costs)

Period of performance should not exceed 2 years

 

Idea Development Award – Preproposal due June 28

Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or

New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award

Are within 10 years of first faculty appointment (or equivalent)

Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research

Emphasis on innovation and impact

New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers

Clinical trials not allowed

Preliminary data required, but may be from outside of lung cancer

Military relevance strongly encouraged

Maximum funding of $350,000 in direct costs (plus indirect costs)

Period of performance should not exceed 2 years

 

Investigator-Initiated Translational Research Award = Preproposal due June 28

Independent investigators at or above the level of Assistant Professor (or equivalent)

Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations

This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:

Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts

Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug submission

Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials

Preliminary data required, but may be from outside of lung cancer

Military relevance strongly encouraged

Maximum funding of $400,000 in direct costs (plus indirect costs)

Period of performance should not exceed 2 years

 

Translational Research Partnership Award – Preproposal due June 28

Investigators at or above the level of Assistant Professor (or equivalent)

Supports partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications

One partner must be from either a Military Treatment Facility or a VA medical center

Non-Traditional Partnerships are encouraged

Small-scale clinical trials allowed

Preliminary data required, but may be from outside of lung cancer

Military relevance strongly encouraged

Maximum combined funding of $900,000 for direct costs (plus indirect costs)

Maximum period of performance is 3 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507

help@ebrap.org

 

Back

 
© National Association of Veterans' Research and Education Foundation. All Rights Reserved.